ME-401, a novel, oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ) in early clinical development for B-cell lymphoid malignancies Meeting Abstract
| Authors: | Ghalie, R. G.; Pagel, J. M.; Soumerai, J.; Iasonos, A.; Patel, K.; Moreno, O.; Butler, T.; Zelenetz, A. D. |
| Abstract Title: | ME-401, a novel, oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ) in early clinical development for B-cell lymphoid malignancies |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 407 |
| Language: | English |
| ACCESSION: | 123459923 |
| DOI: | 10.1002/hon.2439_184 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 474 -- Accession Number: 123459923 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work